Atai Life Sciences Hopes Hercules Can Help ' Sustain ' Operations Until 2026

Photo: Benzinga edit with photo by chrissmith12 and Bru-nO on Pixabay. MDMA derivative EMP-01 for PTSD: A Phase 1 study began in Q3 2022, with initial results expected in H2 2023. Ibogaine DMX-1002 for Opioid Use Disorder (OUD): First subject was dosed in a Phase 1/2 study on 3Q 2022, with initial…#bruno #pixabay #mdma #ibogainedmx1002 #trd #otf #herculescapitalinc #florida
Source: Reuters: Health - Category: Consumer Health News Source Type: news